# Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

> **NCT03275597** · PHASE1 · TERMINATED · sponsor: **University of Wisconsin, Madison** · enrollment: 17 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Non-small Cell Lung Cancer Stage IV

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab
- **RADIATION:** Stereotactic Body Radiotherapy

## Key facts

- **NCT ID:** NCT03275597
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-20
- **Primary completion:** 2020-07-01
- **Final completion:** 2020-07-01
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2023-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03275597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03275597, "Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03275597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*